Related Experiment Video
Updated: Aug 5, 2026
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Primary Peritoneal Perivesical Hemangiosarcoma in 16 Dogs (2020-2024)
Jose Roca1, Xavier Escoda1, Miguel García-de la Virgen2
1Oncology Service Anicura Glòries Hospital Veterinari, Barcelona, Spain.
Veterinary Medicine and Science
|July 29, 2026
Summary
This study characterizes primary peritoneal perivesical hemangiosarcoma (HSA) in dogs, a rare cancer. Multimodal treatments show promise for improving outcomes in canine hemangiosarcoma patients.
Area of Science:
- Veterinary Oncology
- Canine Cancer Research
- Surgical Pathology
Background:
- Canine hemangiosarcoma (HSA) typically affects the spleen, heart, and skin.
- Primary peritoneal HSA, especially perivesical, is rare and poorly understood.
- This study focuses on a unique perivesical peritoneal HSA presentation.
Purpose of the Study:
- To characterize clinical presentation, diagnostics, treatment, and outcomes of dogs with primary peritoneal perivesical HSA.
- To identify prognostic factors and survival times for this specific canine cancer.
- To evaluate the efficacy of different treatment modalities.
Main Methods:
- Retrospective multicentre case series of 16 dogs with peritoneal perivesical HSA.
- Review of medical records for clinical signs, lab results, imaging, and diagnostics.
- Analysis of treatment protocols, metastatic status, progression-free survival (PFS), and disease-specific survival time (DSST).
Main Results:
- Common signs include lethargy, hyporexia, pale mucous membranes, and abdominal distension.
- 50% of dogs presented with hemoperitoneum; 87.5% had metastatic disease.
- Mean PFS and DSST were 125 days; combination therapy improved survival.
Conclusions:
- Primary peritoneal perivesical HSA may be a distinct form of canine HSA.
- Multimodal treatment strategies are crucial for improving outcomes.
- Further research into this rare presentation is warranted.